IN2015DN00542A - - Google Patents
Info
- Publication number
- IN2015DN00542A IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
- Authority
- IN
- India
- Prior art keywords
- compositions
- disorders
- methods
- treating
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000023715 Ocular surface disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to compositions and methods for treating eye diseases and disorders. More specifically the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676530P | 2012-07-27 | 2012-07-27 | |
| US201361756321P | 2013-01-24 | 2013-01-24 | |
| PCT/US2013/052264 WO2014018856A1 (en) | 2012-07-27 | 2013-07-26 | Compositions and treatment for eye diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00542A true IN2015DN00542A (en) | 2015-06-26 |
Family
ID=49997851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN542DEN2015 IN2015DN00542A (en) | 2012-07-27 | 2013-07-26 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150216877A1 (en) |
| EP (1) | EP2877184B1 (en) |
| JP (1) | JP6209777B2 (en) |
| KR (1) | KR102097663B1 (en) |
| CN (2) | CN107595857A (en) |
| AU (1) | AU2013295645B2 (en) |
| BR (1) | BR112015001847A8 (en) |
| CA (1) | CA2880027C (en) |
| DK (1) | DK2877184T3 (en) |
| ES (1) | ES2759781T3 (en) |
| HU (1) | HUE046963T2 (en) |
| IL (1) | IL236920B (en) |
| IN (1) | IN2015DN00542A (en) |
| MX (1) | MX362185B (en) |
| NZ (1) | NZ704247A (en) |
| PL (1) | PL2877184T3 (en) |
| PT (1) | PT2877184T (en) |
| SM (1) | SMT201900678T1 (en) |
| WO (1) | WO2014018856A1 (en) |
| ZA (1) | ZA201500561B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | A PHARMACEUTICAL COMPOSITION COMPRISING SOLUBILIZED ESTRADIOL, PROGESTERONE AND A SOLUBILIZING AGENT, AND USES THEREOF TO TREAT A MENOPAUSE-RELATED SYMPTOM IN A WOMAN |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| ES2649730T3 (en) | 2013-03-15 | 2018-01-15 | Glia Llc | Cranial distribution of pharmaceutical compounds |
| WO2015080758A1 (en) * | 2013-11-27 | 2015-06-04 | Al-Qahtani Ahmed H | Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca |
| RU2016143081A (en) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES |
| EP3171872B1 (en) | 2014-07-21 | 2020-11-11 | Glia, LLC | Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids |
| RU2016141135A (en) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | TRANSDERMAL CREAM |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| KR101960023B1 (en) * | 2016-12-21 | 2019-03-20 | 김보경 | Carbon dioxide generator |
| WO2021163253A1 (en) * | 2020-02-12 | 2021-08-19 | Glia, Llc | Progesterone combinations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102656A (en) | 1983-07-29 | 1992-04-07 | The Mennen Company | Antiperspirant creams |
| US4937069A (en) | 1985-11-15 | 1990-06-26 | Bristol-Myers Squibb Company | Anhydrous semi-solid antiperspirant suspension |
| US5069897A (en) | 1987-10-16 | 1991-12-03 | The Proctor & Gamble Company | Antiperspirant creams |
| US6659985B2 (en) | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| US7572780B2 (en) * | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| NZ584275A (en) * | 2007-10-08 | 2012-06-29 | Fovea Pharmaceuticals | Aqueous cyclosporine ophthalmic formulations |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| CN101757622A (en) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | Drug composition for ocular inflammation resistance |
| US10029013B2 (en) * | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
-
2013
- 2013-07-26 PT PT138234851T patent/PT2877184T/en unknown
- 2013-07-26 HU HUE13823485A patent/HUE046963T2/en unknown
- 2013-07-26 PL PL13823485T patent/PL2877184T3/en unknown
- 2013-07-26 SM SM20190678T patent/SMT201900678T1/en unknown
- 2013-07-26 EP EP13823485.1A patent/EP2877184B1/en active Active
- 2013-07-26 CN CN201710063950.2A patent/CN107595857A/en active Pending
- 2013-07-26 CA CA2880027A patent/CA2880027C/en active Active
- 2013-07-26 WO PCT/US2013/052264 patent/WO2014018856A1/en not_active Ceased
- 2013-07-26 ES ES13823485T patent/ES2759781T3/en active Active
- 2013-07-26 IN IN542DEN2015 patent/IN2015DN00542A/en unknown
- 2013-07-26 CN CN201380039713.2A patent/CN104661663A/en active Pending
- 2013-07-26 KR KR1020157004782A patent/KR102097663B1/en active Active
- 2013-07-26 NZ NZ704247A patent/NZ704247A/en unknown
- 2013-07-26 JP JP2015524465A patent/JP6209777B2/en active Active
- 2013-07-26 AU AU2013295645A patent/AU2013295645B2/en active Active
- 2013-07-26 DK DK13823485T patent/DK2877184T3/en active
- 2013-07-26 MX MX2015001250A patent/MX362185B/en active IP Right Grant
- 2013-07-26 US US14/417,640 patent/US20150216877A1/en not_active Abandoned
- 2013-07-26 BR BR112015001847A patent/BR112015001847A8/en not_active Application Discontinuation
-
2015
- 2015-01-25 IL IL236920A patent/IL236920B/en active IP Right Grant
- 2015-01-26 ZA ZA2015/00561A patent/ZA201500561B/en unknown
-
2016
- 2016-12-15 US US15/380,741 patent/US9925201B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2877184T3 (en) | 2020-04-30 |
| IL236920B (en) | 2018-06-28 |
| HUE046963T2 (en) | 2020-04-28 |
| HK1210968A1 (en) | 2016-05-13 |
| PT2877184T (en) | 2019-12-02 |
| ZA201500561B (en) | 2016-04-28 |
| JP6209777B2 (en) | 2017-10-11 |
| EP2877184A1 (en) | 2015-06-03 |
| ES2759781T3 (en) | 2020-05-12 |
| EP2877184A4 (en) | 2016-03-30 |
| DK2877184T3 (en) | 2019-12-09 |
| NZ704247A (en) | 2018-04-27 |
| CN104661663A (en) | 2015-05-27 |
| AU2013295645B2 (en) | 2017-08-24 |
| MX2015001250A (en) | 2015-10-22 |
| CN107595857A (en) | 2018-01-19 |
| KR20150038311A (en) | 2015-04-08 |
| AU2013295645A1 (en) | 2015-02-05 |
| US20170189413A1 (en) | 2017-07-06 |
| WO2014018856A1 (en) | 2014-01-30 |
| SMT201900678T1 (en) | 2020-03-13 |
| US9925201B2 (en) | 2018-03-27 |
| BR112015001847A8 (en) | 2021-09-08 |
| MX362185B (en) | 2019-01-08 |
| JP2015524434A (en) | 2015-08-24 |
| BR112015001847A2 (en) | 2017-07-04 |
| KR102097663B1 (en) | 2020-04-06 |
| EP2877184B1 (en) | 2019-09-04 |
| US20150216877A1 (en) | 2015-08-06 |
| CA2880027A1 (en) | 2014-01-30 |
| CA2880027C (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00542A (en) | ||
| EP4450130A3 (en) | Formulations of enzalutamide | |
| MX2015012502A (en) | Dna-pk inhibitors. | |
| EP3185876A4 (en) | Compositions and methods for treatment of neurological disorders | |
| EP2709672A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINA DISEASES | |
| EP3212226A4 (en) | Compositions and methods of use for treating metabolic disorders | |
| EP3024497A4 (en) | Methods and compositions for treating brain diseases | |
| EP3174894A4 (en) | Compositions and methods of use for treating metabolic disorders | |
| HK1216175A1 (en) | Therapeutic compounds and compositions | |
| IN2014DN10386A (en) | ||
| EP3160493A4 (en) | Compositions and methods to regulate renalase in the treatment of diseases and disorders | |
| EP3182977A4 (en) | Compositions and methods to treat vision disorders | |
| EP3086809A4 (en) | Compositions and methods of treating ocular diseases | |
| EP2782566A4 (en) | L-SERINE COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | |
| EP3082427A4 (en) | Compositions and methods for treatment of glaucoma | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EP3370709A4 (en) | Use of proteasome inhibitors to treat ocular disorders | |
| MX2016008150A (en) | Berberine formulations and uses thereof. | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| PH12017501694B1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders | |
| EP3003341A4 (en) | Compositions and methods for treatment of retinal degenerative diseases |